Report: US Drugmaker Focused on Profits, not Patients

The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, U.S. Senate investigators said Tuesday. A bipartisan report from the Senate Finance Committee concluded that California-based Gilead Sciences was focused on maximizing revenue even as the company's own analysis showed a lower price would allow more patients to be treated. Although the report focused on just one drug that has made headlines...

© La Voix de l'Amérique - mardi 1^er décembre 2015